UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 221

Sortiert nach

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Journal of clinical oncology, 2012-11, Vol.30 (33), p.4161-4167

2012

Link zum Volltext

Verfügbarkeit prüfen

Synthetic Musks: A Class of Commercial Fragrance Additives in Personal Care Products (PCPs) Causing Concern as Emerging Contaminants

Advances in marine biology, 2018, Vol.81, p.213-280

2018

Link zum Volltext

Verfügbarkeit prüfen

Occurrence, Impact, Analysis and Treatment of Metformin and Guanylurea in Coastal Aquatic Environments of Canada, USA and Europe

Advances in marine biology, 2018, Vol.81, p.23-58

2018

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Blood, 2015-04, Vol.125 (17), p.2649-2655

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

British journal of cancer, 2018-01, Vol.118 (2), p.153-161

2018

Link zum Volltext

Verfügbarkeit prüfen

Understanding Collaborative Art Degree Programs and the Recruitment of International Students

Zhu, Joy Yuhua

2022

Link zum Volltext
ProQuest

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

British journal of cancer, 2018-01, Vol.118 (2), p.e3-e3

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue

Molecular cancer therapeutics, 2011-07, Vol.10 (7), p.1207-1217

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4955: Pegylated recombinant human hyaluronidase PH20 (PEGPH20) increases tumor perfusion in mouse xenografts and phase 1 cancer patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4955-4955

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes

Blood, 2010-11, Vol.116 (21), p.2830-2830

2010

Link zum Volltext

Verfügbarkeit prüfen

Preface

Advances in marine biology, 2018-01, Vol.81, p.xxix-xxx

2018

Link zum Volltext

Verfügbarkeit prüfen

Simplified sample preparation procedure for measuring isotope-enriched methylmercury by gas chromatography and inductively coupled plasma mass spectrometry

Environmental toxicology and chemistry, 2010-06, Vol.29 (6), p.1256-1262

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2579-2579

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15005-e15005

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4010-4010

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3375-3375

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

Blood, 2010-11, Vol.116 (21), p.3292-3292

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

Blood, 2010-11, Vol.116 (21), p.3082-3082

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2672-2672

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB 1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Journal of clinical oncology, 2012, Vol.30 (33), p.4161-4167

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A185-A185

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS)

Blood, 2006-11, Vol.108 (11), p.2657-2657

2006

Link zum Volltext

Verfügbarkeit prüfen

The gammaherpesvirus 68 viral cyclin facilitates expression of LANA

PLoS pathogens, 2021-11, Vol.17 (11), p.e1010019-e1010019

2021

Link zum Volltext

Verfügbarkeit prüfen

A high quantum yield molecule-protein complex fluorophore for near-infrared II imaging

Nature communications, 2017-05, Vol.8 (1), p.15269-15269, Article 15269

2017

Link zum Volltext

Verfügbarkeit prüfen

A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China

The Lancet (British edition), 2021-06, Vol.397 (10293), p.2497-2536

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(199)

Publikationsform

Sprache

Englisch
(221)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(145)
Life Sciences & Biomedicine
(106)
Humans
(67)
Female
(37)
Animals
(34)
Mice
(24)
Technology
(23)
Male
(22)
Physical Sciences
(17)
Science & Technology - Other Topics
(17)
Middle Aged
(16)
Oncology
(16)
Chemistry
(15)
Adult
(14)
Materials Science
(13)
Biological And Medical Sciences
(12)
Multidisciplinary Sciences
(12)
Tumors
(12)
Aged
(11)
Biochemistry & Molecular Biology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Synthetic Musks: A Class of Commercial Fragrance Additives in Personal Care Products (PCPs) Causing Concern as Emerging Contaminants

Occurrence, Impact, Analysis and Treatment of Metformin and Guanylurea in Coastal Aquatic Environments of Canada, USA and Europe

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Understanding Collaborative Art Degree Programs and the Recruitment of International Students

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue

Abstract 4955: Pegylated recombinant human hyaluronidase PH20 (PEGPH20) increases tumor perfusion in mouse xenografts and phase 1 cancer patients

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes

Preface

Simplified sample preparation procedure for measuring isotope-enriched methylmercury by gas chromatography and inductively coupled plasma mass spectrometry

Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors

Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer

A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB 1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS)

The gammaherpesvirus 68 viral cyclin facilitates expression of LANA

A high quantum yield molecule-protein complex fluorophore for near-infrared II imaging

A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China

Suchergebnisse filtern